The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics

Roger A. Rodby; Richard D. Rohde; William R. Clarke; Lawrence G. Hunsicker; Deborah Anzalone; Robert C. Atkins; Eberhard Ritz; Edmund J. Lewis

doi:10.1093/ndt/15.4.487

Abstract

The baseline characteristics of the study subjects are: age 59+/-8 years, duration of diabetes 15+/-9 years, height 168+/-11 cm (5 ft 6 in), weight 87+/-19 kg (192 lb), body mass index 31+/-7 kg/m(2), blood pressure 156+/-18 mmHg/85+/-11 mmHg, serum creatinine 150+/-53 micromol/l (1.7+/-0.6 mg/dl), creatinine clearance 66+/-34 ml/min and 24 h urine protein 4.0+/-3.5 g/day.

Keywords

IrbesartanMedicineDiabetic nephropathyProteinuriaDiabetes mellitusInternal medicineType 2 diabetesNephropathyLosartanAngiotensin IIUrologyEndocrinologyKidneyBlood pressure

Affiliated Institutions

Related Publications

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

Barry M. Brenner , Mark E. Cooper , Dick de Zeeuw +15 more

The RENAAL Study is a double-blind, placebo-controlled trial to evaluate the renal protective effects of losartan in Type 2 diabetic patients with nephropathy. The study has enr...

2000 Journal of the Renin-Angiotensin-Aldo... 138 citations

Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II.

Mordchai Ravid , H Savin , I Jutrin +3 more

Ninety-four normotensive, type II diabetics with microalbuminuria and normal renal function were randomized to receive enalapril or placebo and were followed for five years. In ...

1994 PubMed 63 citations

[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].

Hans‐Henrik Parving , Hendrik Lehnert , Jens Brøchner‐Mortensen +3 more

Irbesartan is renoprotective independently of its blood pressure lowering effect in type 2 diabetic subjects with microalbuminuria. It is safe and well tolerated.

2001 PubMed 2528 citations

Effect of antihypertensive treatment on kidney function in diabetic nephropathy.

Hans‐Henrik Parving , Andreas Andersen , U. Smidt +3 more

The effect of long term, aggressive antihypertensive treatment on kidney function in diabetic nephropathy was studied prospectively in 11 insulin dependent diabetics (mean age 3...

1987 BMJ 548 citations

Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients

Mordchai Ravid

In normotensive patients with diabetes mellitus type II, the institution of angiotensin-converting enzyme inhibition during early stages of diabetic nephropathy results in long-...

1993 Annals of Internal Medicine 784 citations

Publication Info

Year: 2000
Type: article
Volume: 15
Issue: 4
Pages: 487-497
Citations: 128
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

128

OpenAlex

Cite This

APA Style

                            
                                
                                    Roger A. Rodby, 
                                
                                    Richard D. Rohde, 
                                
                                    William R. Clarke
                                
                                et al.
                            
                            (2000). 
                            The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. 
                            Nephrology Dialysis Transplantation
                            , 15
                            (4)
                            , 487-497.
                            https://doi.org/10.1093/ndt/15.4.487
                        

Identifiers

DOI: 10.1093/ndt/15.4.487